Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23038833 | 0.85 | MEN1 (0.45) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL25978287 | 0.85 | MEN1 (0.45) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL25978289 | 0.85 | MEN1 (0.45) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL5280278 | 0.82 | MEN1 (0.43) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL31021350 | 0.81 | KMT2A (0.45) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL15600327 | 0.80 | GAA (0.44) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL2074992 | 0.78 | GAA (0.51) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL25979754 | 0.76 | KMT2A (0.39) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL31168732 | 0.75 | GAA (0.43) | MEN1KMT2AMAPK1GAABTK | |
| SCHEMBL4492849 | 0.75 | BTK (0.58) | MEN1KMT2AMAPK1GAABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334684-B1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-9670216-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2957560-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS | ALLERGAN, INC. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2534137-B1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS | ALLERGAN INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9062004-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2534137-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | Allergan, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2011097553-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | ALLERGAN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010026214-A1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | MEN1 2059/4885KMT2A 1443/4885MAPK1 4008/4885 |
| US-20120115863-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CNR1, CNR2, CHRM5 | MEN1 1874/4885KMT2A 2095/4885MAPK1 1647/4885 |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | MEN1 2186/4885KMT2A 1864/4885MAPK1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.